临床抗青光眼药物的新进展

青光眼是致盲的主要原因之一,构成视神经的神经节细胞轴突受到多种因素的损伤,其机制尚未完全明了。青光眼最重要的危险因素是眼压升高。由于青光眼的视神经损伤尚不能直接治疗,根据目前提供的唯一已知可治疗的危险因素,可以降低升高的眼压,而眼压与房水流出通道的功能息息相关。这些方面的药物均可以影响青光眼的进展。随着医疗技术的发展以及对青光眼发病机制认识的加深,新型抗青光眼药物也应运而生,为眼科医师提供新的选择。本文将对国内外新型抗青光眼药物从机制、药理特点及临床疗效等方面进行综述。

Novel advances in clinical on anti-glaucoma drug

In glaucoma,the ganglion-cell axons that make up the optic nerve are damaged by a variety of factors,only some of which are understood.The most important risk factor for glaucoma is elevated intraocular pressure.Because the optic-nerve damage in glaucoma is not yet amenable to direct treatment,we provide treatment for the only known risk factors that can be modified the elevated intraocular pressure.However，the function of eye pressure is closely related to the function of the flow passage of the aqueous humor.As more is understood about the molecular biology of the trabecular meshwork and optic nerve in health and disease,the ability to treat glaucoma will likely improve.The new glaucoma drugs are also allowed to come into being.This review will focus on the mechanism,pharmacological characteristics and clinical efficacy of new anti-glaucoma drugs at home and abroad.